Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 325

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 325
---
 our common stock issuable in respect of our Series C convertible
preferred stock by 19,731 shares, and a $1.00 increase in the initial public offering price would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 19,254 shares; provided, however,
that in no event would the outstanding shares of our Series C convertible preferred stock convert into more than 3,049,156 shares of our common stock upon the closing of this offering. A 1.0 million share increase in the size of this offering would
increase the number of shares of our common stock issuable in respect of our Series B convertible preferred stock by 4,261 shares, and a 1.0 million share decrease in the size of this offering would decrease the number of shares of our common
stock issuable in respect of our Series C convertible preferred stock by 4,795 shares.

Under our amended and restated certificate of
incorporation that will become effective immediately prior to the closing of this offering, our board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or
more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations, or restrictions
thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current
plans to issue any shares of preferred stock.

Options

As of June 30, 2025, 465,866 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average
exercise price of $43.51 per share. For additional information regarding terms of our equity incentive plans, see the section titled “Executive